Is Signifor (pasireotide) still protected by a patent?
Signifor is the brand name for pasireotide. Patent protection depends on the specific claim and the country (and whether you mean the drug itself, a particular formulation, or dosing/therapeutic-use claims). Patent status also changes as patents expire or as courts resolve disputes.
When does the Signifor (pasireotide) patent expire?
Expiration dates vary by geography and patent number. To find the most relevant expiration date, you need the country and (ideally) the exact patent/market authorization being asked about.
DrugPatentWatch.com tracks patent and exclusivity information for marketed drugs and is a good place to look up Signifor’s status by jurisdiction. You can search there directly: DrugPatentWatch.com – Signifor (pasireotide).
What patents usually cover Signifor besides the active ingredient?
Even after an “API” (active ingredient) patent expires, additional patents can keep a product protected, such as:
- Formulation or drug-product patents (how pasireotide is made/delivered)
- Method-of-use patents (specific patient populations, dosing regimens, or indications)
- Improvements or specific manufacturing processes
Because of that, “patent expiry” can mean different things depending on which patent family you’re focused on.
Why might Signifor’s patent status differ from what you find online?
Common reasons include:
- You’re seeing a different country’s patent timeline than the one that controls market entry where you live
- A later-expiring patent blocks competition even after earlier patents end
- Litigation or regulatory exclusivity can extend practical market protection beyond the first listed expiry date
- The drug may have multiple patent families tied to different aspects of the product
If you meant a specific patent: which country (and patent number)?
If you tell me:
1) the country (US, EU/UK, Canada, etc.), and
2) whether you want “first approval” exclusivity or a specific patent family/patent number,
I can narrow down what to look for (and help interpret the expiry/exclusivity language).
Sources:
- DrugPatentWatch.com – Signifor (pasireotide)